Judith Genevieve Marin

Learn More
BACKGROUND In Europe, epoetin subsequent entry biologics (SEBs) have been in use since 2007. Canadian patents of erythropoietin stimulating agents are expiring in 2014, therefore it is predicted that epoetin SEBs will penetrate the Canadian market in the near future. OBJECTIVE To estimate the economic impact and costs offsets associated with the uptake(More)
PURPOSE OF REVIEW Subsequent entry biologics may soon be a reality in Canadian nephrology practice. Along with opportunities to reduce health care costs, these agents pose unique challenges that must be met for successful implementation. Understanding the experiences around the globe in both regulatory affairs and implementation will be a valuable guide for(More)
BACKGROUND Subsequent entry biologics (SEBs) may soon be a reality in Canadian nephrology practice. Understanding the worldwide experience with these agents will be valuable to Canadian clinicians. OBJECTIVES To compare the efficacy and safety data between SEBs used in nephrology practice and their reference biologic. DESIGN Systematic review. SOURCES(More)
  • 1